ChemoCentryx Inc.

(CCXI) Trade

By |

Profile

ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Contact Information

Website: www.chemocentryx.com
Email: investor@chemocentryx.com
Main Phone: +1 650 210-2900
Address: 850 Maude Avenue
State: CA
City / Town: Mountain View
Country: US
Postal Code: 94043

Issuer Information

Exchange: NGS
CEO: Thomas J. Schall
Employees: 82
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

Profile

ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Contact Information

Website: www.chemocentryx.com
Email: investor@chemocentryx.com
Main Phone: +1 650 210-2900
Address: 850 Maude Avenue
State: CA
City / Town: Mountain View
Country: US
Postal Code: 94043

Issuer Information

Exchange: NGS
CEO: Thomas J. Schall
Employees: 82
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)(541714)

Equities News

$ 48.00 $ -1.52 (-3.07%)
Last Price 48.00 Change $ -1.52 Change % -3.07 Tick N/A
Bid 39.10 Bid Size 500.00 Ask 53.00 Ask Size 500.00
Open 49.06 High 49.38 Low 46.66 Prev Close 49.52
Last Trade Volume 677,513 52 Wk Hi 65.44 52 Wk Low 7.89
Market Cap 3.3 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 68,892,493.00 EPS (TTM) -0.55 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 35 80
Number of Buys 19 43
Number of Sells 16 37
Net Activity 63088 138177
Last 10 Buys Shares
Thomas A. Edwards 1,000
Thomas A. Edwards 1,000
Geoffrey M. Parker 1,000
Geoffrey M. Parker 1,000
Geoffrey M. Parker 1,000
Geoffrey M. Parker 1,000
Geoffrey M. Parker 1,000
Geoffrey M. Parker 1,000
Mark N. Lampert 1,000
Mark N. Lampert 1,000
Last 10 Sell Shares
Thomas J. Schall 1,000
Thomas J. Schall 1,000
Thomas J. Schall 1,000
Markus J. Cappel 1,000
Thomas J. Schall 1,000
Thomas J. Schall 1,000
Markus J. Cappel 1,000
Thomas J. Schall 1,000
Susan M. Kanaya 1,000
Thomas J. Schall 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 20 20 20 20
Low Target Price Estimate 14 14 14 14
Mean Target Price Estimate 17 17 17 17
Standard Deviation 3 3 3 3
Date of Most Recent Estimate 05/16/18 05/16/18 05/16/18 05/16/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 3 2 1 1
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.5 1.67 2 2